Kisqali : Social Media Monitoring Report, Social Media Listening Report

This is a social media monitoring report on US FDA approval of Kisqali (ribociclib) a drug of Novartis for the treatment of Advanced Breast Cancer. Kisqali social media listening report intended to cover following points:

• Quantitative Analysis
  • Quantitative analysis done to map share of online conversation about the approval news on various social media channels.
  • Dominant media type for Kisqali approval new.
  • Topic trend or buzz trend during the monitoring period
  • Top keywords discussed in association with Kisqali through conversation cloud analysis
  • Top hostages and mentions
• Qualitative analysis
  • A high level sentiment analysis to understand people perception and sentiment about the drug’s approval.
  • Top KOLs and interesting verbatim are covered
• Scope to improve on the study
  • A detailed qualitative analysis can be done to understand people perception and sentiment about any specific topics or attributes such. Here is what can be covered in the detailed analysis:
    • Participant’s profiling
    • Perceptions and sentiment by participant type
    • Perceptions and sentiment by attributes such as clinical trial result, efficacy or safety profile, Insurance coverage, etc.
    • Any specific challenges patients are facing
    • Reasons, patient might consider Kisqali for their treatment
    • Barriers and drivers
    • What good looks like and what bad looks like
    • Any campaign/initiative by manufacturer or counter initiatives by competitors and its effectiveness

Any other relevant topic which might come across during the research

Study Background:

• Monitoring period: 1st March till 15th June 17
• Number of Post Analyzed (N): 1233
• Geography covered : USA Only
• Content Analyzed: English

See our recent Social Media Monitoring reports on Kisqali. 

Contact us for qualitative Social Media Listening reports and Pharma Social Media Monitoring Reports.